LDLR and atherosclerosis: Genetic and pharmacological (ABT-263) clearance of excess senescent cells throughout different stages of atherosclerosis improved disease pathology in mouse models of atherosclerosis through ablations of LDL receptor or apolipoprotein E, providing evidence that senescent cells have deleterious effects throughout atherogenesis (7).